Cogent Biosciences

About Cogent Biosciences

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically driven diseases. Their mission is to address the underlying drivers of disease using validated biology, aiming to provide real hope and improved quality of life for patients with unmet medical needs.

Products & Services

Bezuclastinib:A precision therapy targeting systemic mastocytosis and gastrointestinal stromal tumors (GIST), with ongoing clinical trials and an expanded access policy.

Pipeline and Targets:A range of potential therapies in development focusing on genetically defined diseases.

Specialties

Precision therapies Genetically driven diseases Small molecule therapeutics Systemic Mastocytosis Gastrointestinal Stromal Tumors (GIST)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering of Common Stock and Convertible Senior Notes T: - FT: Public Offering of Common Stock and Convertible Senior Notes	A: 475300000 MR: - FA: $475.3 million FAN: 475300000	D: 2025-11-11 FD: 2025-11-11	6 investors
2	RT: Public Offering (Convertible Debt and Equity) T: - FT: Public Offering (Convertible Debt and Equity)	A: 400000000 MR: - FA: $400 million total (proposed $200 million for Convertible Senior Notes and $200 million for Common Stock) FAN: 400000000	D: 2025-11-10 FD: 2025-11-10	6 investors
3	RT: Public Offering T: - FT: Public Offering	A: 230000000 MR: - FA: approximately $230 million FAN: 230000000	D: 2025-07-10 FD: 2025-07-10	4 investors
4	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: $150 million FAN: 150000000	D: 2025-07-08 FD: 2025-07-08	4 investors
5	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: approximately $200 million FAN: 200000000	D: 2025-07-08 FD: 2025-07-08	4 investors
6	RT: Debt T: - FT: Debt	A: 400000000 MR: - FA: up to $400 million FAN: 400000000	D: 2025-06-11 FD: 2025-06-11	1 investors
7	RT: Private Placement T: - FT: Private Placement	A: 225000000 MR: - FA: approximately $225 million FAN: 225000000	D: 2024-02-14 FD: 2024-02-14	10 investors
8	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: approximately $150 million FAN: 150000000	D: 2023-06-09 FD: 2023-06-09	5 investors
9	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: approximately $150 million FAN: 150000000	D: 2023-06-06 FD: 2023-06-06	5 investors
10	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: $125 million FAN: 125000000	D: 2023-06-06 FD: 2023-06-06	5 investors

Public Offering of Common Stock and Convertible Senior Notes Latest

2025-11-11

$475.3M

6 investors (Pro only)

Public Offering (Convertible Debt and Equity) 2025-11-10

$400.0M

Public Offering 2025-07-10

$230.0M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Doug Shipton

Senior Manager, Total Rewards

S

Shannon Winski

Senior Vice President, Translational Science

M

Molly Hord

Sample Administrator

K

Kim Alley

Senior Scientist, Medicinal Chemistry

A

Alex Aubry

Desktop Support Specialist

J

John Trujillo

Senior Team Leader, Medicinal Chemistry

View 40 more team members with Pro

Unlock Full Team Directory

Recent News